Literature DB >> 8042849

Complement activation and inhibition in myocardial ischemia and reperfusion injury.

J W Homeister1, B R Lucchesi.   

Abstract

The myocardial inflammatory response that occurs as a result of ischemia and reperfusion is similar to that which occurs in other tissues. Activation of the complement system is an integral part of the initiation and maintenance of any inflammatory response. It and other immune system mediators participate in the promotion of neutrophil adherence to endothelium by modulating expression of various adhesion molecules. The complement system also serves an integral role in mediating neutrophil activation, the results of which have been documented in the setting of myocardial ischemia and reperfusion. Another aspect of the complement cascade, which has received little attention with respect to the heart, is the direct effects of complement activation such as endothelial and myocardial cell cytotoxicity mediated by the membrane attack complex. It is likely that this form of tissue injury contributes significantly to myocardial reperfusion injury. Given the numerous contributions of the complement system to the generation of the inflammatory response, and to directly-mediated tissue injury, selective inhibitors of the complement system have great potential to limit reperfusion injury. This has already been demonstrated for the complement inhibitor sCR1. In the future, it is likely that any therapeutic treatment of reperfusion injury will include modulation of the effects of complement activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042849     DOI: 10.1146/annurev.pa.34.040194.000313

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  15 in total

1.  Myocardial Reperfusion Injury: From Bench to Bedside.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Pathobiology and Clinical Impact of Reperfusion Injury.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

Review 4.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Complement and contact activation in term neonates after fetal acidosis.

Authors:  J Sonntag; M H Wagner; E Strauss; M Obladen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

Review 6.  Innate immunity and the failing heart: the cytokine hypothesis revisited.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

Review 7.  Linking acute kidney injury to chronic kidney disease: the missing links.

Authors:  Mohammed A Kaballo; Mohamed E Elsayed; Austin G Stack
Journal:  J Nephrol       Date:  2016-12-07       Impact factor: 3.902

8.  Reperfusion injury after myocardial infarction.

Authors:  B P Morgan
Journal:  BMJ       Date:  1995-05-27

Review 9.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 10.  Innate immunity in donor procurement.

Authors:  Kitty P Cheung; Sashi G Kasimsetty; Dianne B McKay
Journal:  Curr Opin Organ Transplant       Date:  2013-04       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.